Fresenius Medical Care's Surprise CEO Change Raises Questions on Outlook
Dow Jones
Oct 08
0707 GMT - Fresenius Medical Care's surprise CEO change will be taken negatively by investors and points to a challenging outlook for the German dialysis specialist, analysts at J.P. Morgan say. The departure of CEO Helen Giza comes less than 18 months after she presented an ambitious business plan with guidance through 2030, the analysts say in a research note. Her exit suggests it is now less likely the company will be able to demonstrate the benefits from the rollout of a new dialysis technology in the U.S., they add. The end of regulatory tailwinds that recently flattered the group's results mean Fresenius Medical Care could be set for an operating profit contraction, according to JPM. Shares fall 2.7%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.